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Assessment of Comprehensibility of Industry Conflicts of Interest and Disclosures
by Multiple Sclerosis Researchers at Medical Conferences
Sarah-Jane Martin, MBChB; David P. J. Hunt, MBBChir, PhD
Introduction
Financial relationships between health care professionals and the pharmaceutical industry should be
transparent, especially in influential arenas such as medical conferences. Typically, a disclosure slide
is mandated at the start of every conference presentation to inform the audience of the presenter’s
conflicts of interest (COIs). However, the comprehensibility of this disclosure is dependent on the
transparency behavior of the presenter, who decides how long the slide—together with its COI
information content—is displayed.
The potential for industry payments to influence physician behavior has elicited concern in
many fields of health care.1 The field of multiple sclerosis research has recently come under particular
scrutiny. Concerns have been expressed regarding industry influence on researcher behavior2 in the
context of dramatic drug cost increases not seen in other specialties.3 We therefore measured the
association between the intensity of industry COIs and the transparency behavior among individuals
who delivered oral presentations at the world’s largest multiple sclerosis conference.
Methods
We conducted a cross-sectional study to analyze the information content of the COI disclosure slide
at platform presentations at the Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden, in 2019. Using the information displayed in the
slide presented in the ECTRIMS Online Library, we recorded the total number of companies in which
the presenter declared a personal COI (eMethods in the Supplement). We determined the intensity
of the COI by classifying individual presenters’ COIs into the following categories: “no conflicts” (no
COIs), “some conflicts” (1 COI but <10), and “heavy conflicts” (10 COIs). We then assessed the
following transparency behaviors for each presentation: (1) the length of time the disclosure slide
was displayed, compiled by one author (S.-J.M.) using the video player time stamp and the second
author (D.P.J.H.) using a stopwatch, and (2) the word count of the slide, compiled either by manual
counting or use of the word count function in Word (Microsoft Corp) for disclosures longer than 100
words. This study involved analysis of publicly available datasets only. As such, research ethics
committee review was not required, following the guidance and regulations of the NHS Health
Research Authority. This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.
Physicians based in the United States are mandated to declare details of industry payments. We
used the Open Payments search tool from the Centers for Medicare and Medicaid Services to
investigate the mean value of each declared industry conflict for US-based conference speakers for
the 3 years before the 2019 conference. The correlation between the number of COIs and length of
display time of the disclosure slide was calculated using the Spearman rank correlation coefficient.
Comparison of the proportion of readable disclosures between COI groups was performed using a χ2
test for trend. Statistical analyses, descriptive statistics, and linear regression were performed using
Prism version 8 (GraphPad). The level of statistical significance was set at 2-sided P < .05.
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Results
We assessed 240 oral presentations at the 2019 annual ECTRIMS Congress. Of these presentations,
57 (24%) were delivered by researchers with no conflicts, 160 (66%) by researchers with some
conflicts, and 23 (10%) by researchers with heavy conflicts. We found an inverse correlation between
the number of COIs of the presenter and length of display time of the disclosure slide (rs = −0.24;
P < .001) (Figure 1).
We then assessed whether the length of display time of the disclosure slide was sufficient for
meaningful comprehension of the slide contents. The mean time of display for the disclosure slide
was 6.0 seconds in talks when the presenters had no conflicts (95% CI, 4.3-7.8 seconds; Figure 2A),
4.7 seconds for those with some conflicts (95% CI, 3.8-5.6 seconds), and 2.9 seconds for those with
heavy conflicts (95% CI, 2.1-3.9 seconds). To assess whether these slide display times were sufficient
for full comprehension of the presenter’s conflicts of interest, we classified a disclosure slide as
“readable” if the total number of words in the slide could be read in full at the average reading speed
(3.8 words/s).4 Disclosure statements exhibited at faster rates were classified as “not readable.” Of
the 57 presentations by individuals with no conflicts, 21 (37%) were readable compared with 18 of
160 presentations (11%) by individuals with some conflicts, and none of the 23 presentations by
individuals with heavy conflicts (χ2 for trend = 23; P < .001) (Figure 2B). The mean disclosure slide
Figure 1. Intensity of Industry Conflicts of Interest and Length of Disclosure Slide Display Time




























rs =−0.24, P <.001
An inverse correlation existed between the number of
industry conflicts of interest and the length of display
times of the disclosure slide. Each circle represents an
individual presentation (n = 240). The solid blue line
represents the estimated linear association, with 95%
CI (shaded section).








































































A, Mean length of display time of disclosure slide by
conflicts of interest category. Error bars indicate 95%
CIs. B, Proportion of readable disclosure statements by
conflicts of interest category.
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reading rate from the group with heavy (10) conflicts was approximately 40 words/s, more than 10
times faster than the average reading speed.4 For the 31 US-based physicians who were presenters
at this conference, there was a strong correlation between the number of declared COIs and the
amount of personal payments from industry (rs = 0.77; P < .001). The mean financial value of each
declared COI was $23 500.
Discussion
Conflicts of interest with the pharmaceutical industry should be clearly declared. This study’s findings
suggest an inverse association between transparency behavior at conferences and the degree of
personal COIs. Presentations from individuals with strong links to industry might be anticipated to
require a longer time to explain their disclosures. However, our analysis shows that such
presentations are associated with shorter slide display times, resulting in a speed of delivery that
almost always prevents adequate comprehension.
Industry conflicts have been shown to influence individual physician behaviors, such as
prescription of brand name drugs.1 The findings of this cross-sectional study suggest that such
conflicts may also have the potential to influence other behaviors, resulting in reduced transparency.
We used the number of personal industry conflicts as a primary measure of the level of industry
influence, rather than the financial value of industry payments. This limitation arose because many
speakers outside the United States are not legally required to declare the value of these transactions.
Further limitations of our study were a potential bias toward European speakers and restriction of
the analysis to presenters at a single international conference.
Concerns about transparency and disclosure comprehensibility have been raised across medical
specialties.5,6 Together, these findings raise serious questions about the adequacy of the current
disclosure system at medical conferences. Simple, standardized, and readable disclosure statements
are urgently needed at the point of influential data presentation.
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